United Kingdom-based GlaxoSmithKline's respiratory drug Nucala (mepolizumab) has succeeded in decreasing flares in patients with hypereosinophilic syndrome in a phase three study, it was reported yesterday.
The late-stage study assessed subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult patients with severe HES, an illness that causes patients to have a persistent and notable overproduction of eosinophils.
The HES trial met its primary endpoint of delivering a statistically significant result with 50% less patients experiencing a hypereosinophilic flare in the mepolizumab arm, compared to placebo. The product was assessed for its efficacy and safety in combination with standard of care treatment over the 32-week study period. The firm stated that the late-stage trial's secondary endpoints were also significant statistically, while supporting the primary endpoint.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic